38647-79-9 Usage
Uses
Used in Pharmaceutical Industry:
Urefibrate is used as a cholesterol-lowering agent for reducing high cholesterol and triglyceride levels in the blood. It aids in the management of dyslipidemia by decreasing cholesterol production and increasing the breakdown of triglycerides, thereby lowering the risk of cardiovascular diseases.
Used in Anti-Inflammatory Applications:
Urefibrate is used as an anti-inflammatory agent due to its ability to reduce inflammation, which can contribute to the development of various health conditions, including cardiovascular diseases.
Used in Insulin Sensitivity Improvement:
Urefibrate is used to enhance insulin sensitivity, which can be beneficial for individuals with insulin resistance or type 2 diabetes, helping to regulate blood sugar levels and reduce the risk of complications associated with these conditions.
Used in Cardiovascular Disease Prevention:
Urefibrate is used as a preventive medication to lower the risk of cardiovascular diseases by managing lipid profiles and reducing inflammation, which are key factors in the development of atherosclerosis and other cardiovascular conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 38647-79-9 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 3,8,6,4 and 7 respectively; the second part has 2 digits, 7 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 38647-79:
(7*3)+(6*8)+(5*6)+(4*4)+(3*7)+(2*7)+(1*9)=159
159 % 10 = 9
So 38647-79-9 is a valid CAS Registry Number.
InChI:InChI=1/C15H12Cl2N2O4/c16-9-1-5-11(6-2-9)22-14(13(20)19-15(18)21)23-12-7-3-10(17)4-8-12/h1-8,14H,(H3,18,19,20,21)
38647-79-9Relevant articles and documents
Synthesis and pharmacological evaluation of N'-morpholinomethylurea derivatives with platelet antiaggregant activity
Ribalta,Artus,Salvador,Roma,Vilageliu,Freixes,Bruseghini
, p. 1782 - 1786 (2007/10/02)
In the attempt to prolong and stabilize the known antiaggregant activity of morpholinomethylurea (MMU) derivatives were prepared with carboxylic acids possessing antiaggregant, antiinflammatory or hypolipemic activity. The results of the experiments showed the important anti-aggregant and hypolipemic activity of N-2(p-chlorophenoxy)-isobutyryl-N'-morpholinomethylurea (plafibride, ITA 104). The results obtained seem to indicate that the activity of these new N-acyl-N'-MMU is due initially to the molecule per se although it cannot be totally ruled out that part of the pharmacodynamic effect of the MMU may depend on a prodrug-like behaviour.